Randomized trial assesses adjunctive lumateperone's safety and efficacy in major depressive disorder, suggesting potential benefits for inadequate antidepressant therapy.
Objective: Lumateperone, a mechanistically novel antipsychotic, simultaneously modulates serotonin, dopamine, and glutamate neurotransmission. This phase 3, randomized, double-blind, placebo-controlled trial investigated efficacy and safety of adjunctive lumateperone 42 mg in patients with major depressive disorder (MDD) with inadequate antidepressant therapy (ADT) response.
No takes yet. Share an insight, caveat, or question.
Durgam et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: